Paolo Antonio Ascierto

Paolo Antonio Ascierto's AcademicInfluence.com Rankings

Medical

#1261

World Rank

#1581

Historical Rank

Oncology

#51

World Rank

#54

Historical Rank

medical Degrees

Paolo Antonio Ascierto

Philosophy

#4164

World Rank

#6574

Historical Rank

Logic

#1685

World Rank

#2499

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Paolo Antonio Ascierto's Degrees

Doctorate Medicine University of Naples Federico II
PhD Oncology University of Naples Federico II

Why Is Paolo Antonio Ascierto Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Paolo Antonio Ascierto's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. (2011) (5546)
Nivolumab in previously untreated melanoma without BRAF mutation. (2015) (4628)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (2015) (3858)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (2017) (2731)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. (2015) (2259)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. (2019) (1781)
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. (2014) (1716)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma (2017) (1456)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. (2015) (1348)
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study (2018) (1224)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. (2020) (1193)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (2018) (1137)
Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours (2013) (1136)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. (2016) (1048)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. (2015) (978)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. (2016) (975)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. (2012) (819)
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. (2014) (792)
Cancer classification using the Immunoscore: a worldwide task force (2012) (719)
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. (2016) (712)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. (2018) (629)
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. (2013) (578)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. (2018) (577)
The role of BRAF V600 mutation in melanoma (2012) (565)
The immune score as a new possible approach for the classification of cancer (2012) (542)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab (2016) (449)
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. (2012) (443)
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab (2016) (442)
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. (2017) (398)
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer (2018) (381)
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. (2013) (381)
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. (2018) (372)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. (2017) (344)
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. (2017) (312)
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy (2014) (307)
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. (2022) (301)
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial (2020) (300)
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. (2010) (282)
Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma (2005) (282)
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab (2018) (260)
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. (2012) (258)
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. (2014) (246)
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody (2016) (243)
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma (2014) (240)
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. (2005) (232)
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable (2019) (230)
Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. (2017) (229)
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial (2019) (224)
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma (2019) (216)
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. (2020) (213)
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo (2020) (212)
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. (2015) (211)
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. (2016) (208)
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus (2020) (207)
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. (2017) (206)
Main roads to melanoma (2009) (197)
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) (2019) (183)
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. (2018) (183)
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial (2019) (181)
Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. (2017) (175)
Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination (2013) (174)
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study (2017) (169)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events (2021) (168)
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. (2010) (164)
Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma . (2012) (163)
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. (2015) (159)
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort (2014) (157)
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer (2020) (156)
Mucosal melanoma of the head and neck. (2017) (154)
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma (2021) (153)
Defining the critical hurdles in cancer immunotherapy (2011) (152)
The influence of diet on anti-cancer immune responsiveness (2018) (150)
Gemcitabine versus bacille Calmette‐Guérin after initial bacille Calmette‐Guérin failure in non‐muscle‐invasive bladder cancer (2010) (150)
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. (2018) (148)
Survival of patients with advanced metastatic melanoma: The impact of novel therapies. (2016) (146)
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. (2020) (146)
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (144)
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019) (140)
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. (2019) (139)
Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types (2013) (138)
Systemic Therapy for Melanoma: ASCO Guideline. (2020) (137)
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. (2014) (132)
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. (2017) (131)
NF-κB as potential target in the treatment of melanoma (2012) (131)
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use (2012) (129)
Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. (2013) (128)
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab (2016) (128)
Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015 (2016) (125)
Human Melanoma Metastases Express Functional CXCR4 (2006) (125)
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. (2019) (124)
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade (2019) (124)
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? (2016) (124)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) (119)
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial (2020) (116)
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) (2018) (114)
Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma (2016) (114)
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment (2013) (113)
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. (2015) (111)
PD-1 Blockade in Anaplastic Thyroid Carcinoma (2020) (110)
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases (2014) (110)
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. (2020) (110)
Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. (1999) (103)
LBA18Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations (2017) (103)
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. (2019) (103)
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. (2019) (98)
PD-L1 expression as a potential predictive biomarker. (2015) (97)
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme (2014) (96)
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program (2014) (96)
miR-579-3p controls melanoma progression and resistance to target therapy (2016) (95)
MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors (2017) (94)
Anti-IL6R role in treatment of COVID-19-related ARDS (2020) (94)
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice (2020) (92)
Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. (2003) (91)
MicroRNAs in melanoma development and resistance to target therapy (2017) (90)
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma (2015) (90)
Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). (2021) (88)
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets (2015) (88)
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. (2018) (88)
CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). (2016) (88)
Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. (2017) (87)
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (2020) (87)
Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. (2016) (87)
Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells (2005) (87)
Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects (2014) (86)
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial (2022) (85)
Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1 (2012) (84)
Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients (2013) (83)
Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study (2016) (83)
2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond (2015) (83)
Adjuvant therapy of melanoma with interferon: lessons of the past decade (2008) (83)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. (2019) (82)
Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. (2014) (81)
Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients. (2016) (80)
ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee. (2020) (79)
Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. (2020) (79)
Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study (2017) (78)
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. (2013) (78)
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma (2020) (78)
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response (2020) (77)
Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion (2020) (76)
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. (2017) (74)
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application (2011) (73)
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. (2017) (73)
Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. (2017) (71)
Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study. (2016) (70)
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma (2020) (70)
MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA (2018) (69)
Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial (2019) (69)
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. (2020) (68)
Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay. (2001) (68)
Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma (2018) (68)
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy (2020) (68)
Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). (2018) (66)
Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2731 excised cutaneous pigmented lesions (2000) (65)
Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy (2015) (65)
Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC. (2019) (64)
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. (2020) (64)
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab (2017) (64)
Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy (2018) (64)
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells (2017) (62)
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients (2013) (62)
A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. (2015) (61)
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials (2018) (60)
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 (2020) (60)
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. (2018) (59)
Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies (2013) (59)
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i (2020) (59)
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients (2017) (58)
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. (2014) (57)
LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial (2020) (57)
Molecular detection and targeting of EWSR1 fusion transcripts in soft tissue tumors (2013) (57)
Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. (2015) (57)
Interleukin 18: friend or foe in cancer. (2013) (57)
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop (2019) (57)
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. (2021) (57)
386PEfficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers (2017) (56)
BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study. (2004) (56)
Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. (2012) (55)
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. (2020) (55)
EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results (2008) (55)
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. (2019) (55)
Future perspectives in melanoma research (2016) (54)
Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis (2013) (54)
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy (2014) (53)
Combination therapy: the next opportunity and challenge of medicine (2011) (52)
Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy? (2017) (52)
Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases (2005) (52)
Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment (2016) (51)
A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma (2017) (51)
Serious haematological toxicity during and after ipilimumab treatment: a case series (2014) (50)
Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care (2017) (50)
The use of interferon in melanoma patients: a systematic review. (2015) (50)
Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma (2007) (49)
Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study (2013) (49)
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition (2021) (49)
Computer-aided diagnosis of melanocytic lesions. (2005) (49)
Covid‐19: Time for a paradigm change (2020) (48)
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study (2018) (48)
Immunological effects of BRAF+MEK inhibition (2018) (48)
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. (2016) (48)
Prognostic value of serum VEGF in melanoma patients: a pilot study. (2004) (48)
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. (2019) (48)
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma (2016) (47)
Evolving impact of long-term survival results on metastatic melanoma treatment (2020) (46)
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. (2019) (46)
Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. (2017) (46)
HOTAIR role in melanoma progression and its identification in the blood of patients with advanced disease (2017) (46)
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma (2018) (45)
Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 (2015) (45)
Genetic alterations in main candidate genes during melanoma progression (2018) (45)
Clinical genetic testing for familial melanoma in Italy: a cooperative study. (2009) (45)
KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma. (2018) (45)
Increased HOX C13 expression in metastatic melanoma progression (2012) (44)
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). (2019) (44)
Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy (2009) (44)
Melanoma: A model for testing new agents in combination therapies (2010) (44)
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study (2016) (44)
Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. (2015) (43)
Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma (2018) (43)
Novel approaches in melanoma prevention and therapy. (2014) (42)
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma (2015) (42)
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 (2013) (42)
Electrochemotherapy as "new standard of care" treatment for cutaneous Kaposi's sarcoma. (2014) (41)
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma (2020) (41)
Results of COLUMBUS Part 2: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus ENCO in BRAF - Mutant Melanoma (2017) (41)
The role of MEK inhibitors in the treatment of metastatic melanoma (2014) (41)
Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases (2000) (41)
CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type (2007) (40)
Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma. (2021) (40)
Microenvironment and tumor progression of melanoma: New therapeutic prospectives (2012) (40)
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program (2020) (40)
What’s new in melanoma? Combination! (2015) (39)
Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. (2015) (39)
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma (2022) (39)
Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment (2010) (39)
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study (2021) (38)
ESMO consensus conference recommendations on the management of locoregional melanoma: the ESMO Guidelines Committee. (2020) (38)
Frontline Therapy for BRAF-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer? (2019) (38)
CheckMate 067: Long-term outcomes in patients with mucosal melanoma. (2020) (38)
Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. (2007) (37)
Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases (2003) (37)
Expression of CXCR 4 Predicts Poor Prognosis in Patients with Malignant Melanoma (2005) (37)
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma (2021) (37)
PD-L1 inhibitors in the pipeline: Promise and progress (2018) (37)
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma (2020) (37)
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. (2017) (37)
Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. (2016) (37)
Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study (2013) (36)
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis (2019) (36)
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment (2014) (36)
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. (2016) (36)
Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy? (2017) (36)
Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961. (2010) (36)
Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma (2019) (36)
Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations (2019) (36)
Issues affecting molecular staging in the management of patients with melanoma (2007) (36)
PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab (2017) (35)
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future? (2017) (35)
Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. (2019) (35)
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. (2020) (35)
Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer. (2018) (35)
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. (2019) (34)
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma (2013) (34)
Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations (2013) (34)
Cd40 Activation as Potential Tool in Malignant Neoplasms (2002) (34)
Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. (2013) (34)
Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (33)
Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review. (2020) (33)
NEMO-binding domain peptide inhibits proliferation of human melanoma cells. (2009) (33)
Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series (2016) (33)
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma. (2016) (33)
The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014 (2014) (33)
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I. (2019) (32)
What have we learned from cancer immunotherapy in the last 3 years? (2014) (32)
Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma (2014) (32)
Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study (2017) (32)
NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug (2012) (32)
Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma (2015) (32)
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. (2021) (32)
The immune-related role of BRAF in melanoma (2014) (31)
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma (2011) (31)
Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib (2017) (31)
Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D). (2017) (30)
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma (2020) (30)
Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma (2017) (30)
Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma (2019) (30)
Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2731 excised cutaneous pigmented lesions. The Melanoma Cooperative Study. (2000) (30)
Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial (2020) (30)
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy (2020) (30)
Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy (2015) (29)
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. (2017) (29)
Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma (2012) (29)
Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL). (2015) (29)
IL-6 modulation for COVID-19: the right patients at the right time? (2021) (29)
Unexpected Distribution of cKIT and BRAF Mutations among Southern Italian Patients with Sinonasal Melanoma (2013) (29)
An assessment of factors related to tumor thickness and delay in diagnosis of melanoma in southern Italy. (2002) (29)
Break-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets) (2012) (29)
Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis (2017) (28)
Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies (2019) (28)
Integrating first-line treatment options into clinical practice: what’s new in advanced melanoma? (2015) (28)
Do BRAF inhibitors select for populations with different disease progression kinetics? (2013) (28)
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). (2019) (27)
Emerging Strategies in Systemic Therapy for the Treatment of Melanoma. (2018) (27)
New paradigm for stage III melanoma: from surgery to adjuvant treatment (2019) (27)
Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma (2016) (27)
Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. (2016) (26)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study. (2020) (26)
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. (2018) (26)
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. (2021) (26)
Sun exposure and melanoma prognostic factors (2016) (26)
World-Wide Immunoscore Task Force: meeting report from the “Melanoma Bridge”, Napoli, November 30th–December 3rd, 2016 (2017) (26)
coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) (2015) (26)
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies. (2020) (26)
Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. (2020) (26)
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee (2020) (26)
Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma. (2019) (26)
Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway (2019) (25)
Discrepant alterations in main candidate genes among multiple primary melanomas (2014) (25)
Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study). (2012) (25)
Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. (2011) (25)
Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis. (2019) (25)
The cost of unresectable stage III or stage IV melanoma in Italy (2012) (25)
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients (2019) (25)
Epiluminescence microscopy as a useful approach in the early diagnosis of cutaneous malignant melanoma (1998) (25)
MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial (2017) (25)
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study (2017) (24)
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme (2013) (24)
Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway. (2015) (24)
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. (2021) (24)
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma (2019) (24)
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma (2013) (24)
Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma? (2018) (24)
Expression of the anti-apoptotic protein BAG3 in human melanomas. (2012) (24)
Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. (2016) (24)
Corrigendum: Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab. [Ann Oncol 27, (2016), (732-738)] doi:10.1093/annonc/mdw016. (2016) (24)
Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915) (2021) (24)
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy (2017) (24)
Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report (2012) (23)
Sentinel lymph node biopsy does not change melanoma-specific survival among patients with breslow thickness greater than four millimeters (2004) (23)
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma. (2018) (23)
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee (2020) (23)
Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study (2019) (23)
A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma. (2017) (23)
Sentinel lymph node biopsy in patients with cutaneous melanoma: outcome after 3-year follow-up. (2004) (23)
Pembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: Updated Analysis from the Phase 2 KEYNOTE-158 Study. (2022) (23)
Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study. (2018) (22)
Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma (2015) (22)
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis (2020) (22)
PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis (2016) (22)
Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients (2015) (22)
Cisplatin, dacarbazine, and fotemustine plus interferon α in patients with advanced malignant melanoma (2000) (22)
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma (2018) (22)
LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study) (2020) (22)
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy (2020) (22)
Anti-PD-1 and PD-L1 antibodies in metastatic melanoma. (2017) (22)
Soluble interleukin-2 receptor in stage I-III melanoma. (2006) (22)
LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study (2021) (22)
Early diagnosis of malignant melanoma: Proposal of a working formulation for the management of cutaneous pigmented lesions from the Melanoma Cooperative Group. (2003) (21)
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib. (2020) (21)
Phenotype characterization of human melanoma cells resistant to dabrafenib (2017) (21)
Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68 (2011) (21)
Immunological Phenotype Analysis of Patients with Fanconi’s Anaemia and Their Family Members (1998) (21)
ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin (2019) (21)
SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression (2014) (21)
Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up. (2020) (21)
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice (2019) (20)
Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL) (2016) (20)
FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” (2012) (20)
Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients (2020) (20)
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM (2019) (20)
Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management (2020) (20)
Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172). (2017) (20)
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT) (2016) (20)
Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors (2013) (20)
Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors. (2019) (20)
Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma (2019) (19)
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma (2018) (19)
Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma (2006) (19)
Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents (2022) (19)
The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era (2019) (19)
SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study (2021) (19)
Cosmic radiation and cancer: is there a link? (2015) (19)
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial (2022) (19)
Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study. (2015) (19)
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”, Napoli, December 5th-8th 2013 (2014) (19)
No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study (2021) (18)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) (18)
Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach (2019) (18)
Neoadjuvant therapy in melanoma: the next step? (2018) (18)
Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients. (2013) (18)
Single versus combination immunotherapy drug treatment in melanoma (2016) (18)
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7 th2010" (2011) (18)
Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy (2021) (18)
Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial (2016) (18)
Clinical significance of PCR-positive mRNA markers in peripheral blood and regional nodes of malignant melanoma patients. Melanoma Cooperative Group. (2001) (18)
When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report (2020) (18)
Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided. (2019) (17)
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. (2011) (17)
Temozolomide and cisplatin in avdanced malignant melanoma. (2005) (17)
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment (2022) (17)
Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC). (2016) (17)
Update on PEG-interferon α-2b as adjuvant therapy in melanoma. (2012) (17)
Tumor biobanks in translational medicine (2012) (17)
Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management (2019) (17)
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. (2022) (17)
Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. (2021) (17)
HHV-8 prevalence, immunosuppression and Kaposi's sarcoma in South Italy. (2001) (17)
Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group. (2000) (17)
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations (2019) (17)
MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors (2020) (17)
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. (2020) (16)
Who benefits most from adjuvant interferon treatment for melanoma? (2015) (16)
EGFR mutational status in penile cancer (2013) (16)
1213OCharacterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone (2017) (16)
Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS (2020) (16)
Lean oncology: a new model for oncologists (2012) (16)
Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial. (2019) (16)
LBA35OVERALL SURVIVAL AND BIOMARKER RESULTS FROM A PHASE 2 STUDY OF MEK1/2 INHIBITOR BINIMETINIB (MEK162) IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA (2014) (16)
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016 (2017) (16)
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis (2022) (16)
The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer (2016) (16)
Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients (2012) (15)
Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival. (2012) (15)
Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells (2017) (15)
Phase I/II multicenter trial of a novel therapeutic cancer vaccine, HepaVac-101, for hepatocellular carcinoma. (2022) (15)
CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer (2019) (15)
First line treatment of BRAF mutated advanced melanoma: Does one size fit all? (2021) (15)
The role of spectrophotometry in the diagnosis of melanoma (2010) (15)
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. (2018) (15)
MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness (2010) (15)
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective (2020) (15)
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. (2022) (14)
Real‐world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab (2018) (14)
Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma. (2016) (14)
The immune‐related role of BRAF in melanoma (2014) (14)
Adjuvant therapy of cutaneous melanoma (1999) (14)
Mutation analysis of candidate genes in melanoma-prone families: evidence of different pathogenetic mechanisms at chromosome 9p21 (2003) (14)
Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study. (2017) (14)
Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP). (2013) (14)
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas (2015) (14)
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma (2016) (14)
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC) (2022) (13)
Melanoma and other skin tumors (2012) (13)
Epigenetic Regulation in Melanoma: Facts and Hopes (2021) (13)
An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma. (2012) (13)
Prospective clinical trials of biotherapies in solid tumors: a 5-year survey (2004) (13)
Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications. (2008) (13)
results from a randomised, double-blind, phase 3 trial (2016) (13)
Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma (2021) (13)
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016 (2017) (13)
Melanoma and immunotherapy bridge 2015 (2016) (13)
Melanoma and immunotherapy bridge 2015 (2016) (13)
Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters (2014) (13)
Molecular classification of patients with malignant melanoma for new therapeutic strategies. (2007) (13)
Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238) (2017) (13)
LBA7_PRBRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence (2017) (13)
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. (2022) (13)
Cancer Immunotherapy Principles and Practice (2018) (13)
The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series. (2018) (13)
Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047) (2022) (13)
Management of cutaneous melanoma: radiologists challenging and risk assessment (2022) (13)
Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. (2019) (13)
Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. (2018) (13)
Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study (2018) (13)
A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy (2017) (12)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology (2016) (12)
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP). (2013) (12)
Immune Checkpoint Inhibitors in Melanoma and HIV Infection (2017) (12)
The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies (2021) (12)
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy) (2019) (12)
Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study (2021) (12)
A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence (2015) (12)
Ran signaling in melanoma: implications for the development of alternative therapeutic strategies. (2015) (12)
the critical hurdles in cancer immunotherapy (2012) (12)
Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells (2018) (12)
Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone (2016) (12)
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy) (2018) (12)
A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial. (2011) (12)
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists (2020) (12)
In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma (2020) (12)
Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. (2018) (12)
Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better? (2021) (12)
Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy) (2018) (12)
The Role of Optical Radiations in Skin Cancer (2013) (12)
Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advancedBRAFV600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i (2018) (12)
TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol (2020) (11)
Melanoma immunotherapy: strategies to overcome pharmacological resistance (2020) (11)
MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab (2014) (11)
25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study (2015) (11)
May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)? (2020) (11)
Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C (2017) (11)
Prognostic Value of CD40 in Adult Soft Tissue Sarcomas (2004) (11)
Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511). (2018) (11)
LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial (2021) (11)
A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results (2021) (11)
Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma (2015) (11)
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma (2019) (11)
NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma. (2014) (11)
Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial. (2019) (11)
Efficacy of cobimetinib (C) and vemurafenib (V) in advanced BRAF-mutated melanoma patients (pts) with poor and favorable prognosis in the coBRIM phase III study. (2016) (11)
Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies. (2013) (11)
Adjuvant treatment of malignant melanoma: where are we? (2006) (11)
Translational significance of Nodal, Cripto-1 and Notch4 in adult nevi (2016) (10)
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) (2022) (10)
Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015 (2016) (10)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Mutations in ERBB4 may have a minor role in melanoma pathogenesis. (2013) (10)
Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study. (2017) (10)
3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma (2015) (10)
Outcomes of ipilimumab treatment-related adverse events in patients with metastatic melanoma (MM) who received systemic corticosteroids in a phase III trial. (2012) (10)
FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy (2017) (10)
BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas (2019) (10)
The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study (2018) (10)
MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies (2018) (10)
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib (2016) (10)
Immunoscore: a new possible approach for melanoma classification (2014) (10)
Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032. (2018) (10)
A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2). (2020) (10)
An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. (2019) (10)
Intermediate dose recombinant interferon‐α as second‐line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon (2000) (10)
The soluble interleukin‐2 receptor as an indicator of clinical evolution in patients with ulcerative colitis (1997) (10)
1244PHospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma (2017) (10)
Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy. (2018) (10)
Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): Results of a phase III study (CheckMate 066). (2015) (10)
Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients. (2013) (10)
Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report (2014) (9)
Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI) (2020) (9)
Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification (2014) (9)
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors (2020) (9)
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. (2021) (9)
Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763). (2014) (9)
Expanded access programmes: patient interests versus clinical trial integrity. (2015) (9)
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival (2020) (9)
The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts (2022) (9)
Clinical and dermoscopic criteria related to melanoma sentinel lymph node positivity. (2007) (9)
Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls (2009) (9)
Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients (2015) (9)
Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial (2011) (9)
Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts). (2016) (9)
1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone (2020) (9)
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma (2022) (9)
1130TiPNEMO: A PHASE 3 TRIAL OF BINIMETINIB (MEK162) VERSUS DACARBAZINE IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA WHO ARE UNTREATED OR HAVE PROGRESSED AFTER ANY NUMBER OF IMMUNOTHERAPY REGIMENS. (2014) (9)
Efficacy of vemurafenib in BRAFV600K mutation positive melanoma disease - results from the phase III clinical study BRIM-3. (2011) (9)
Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis (2021) (9)
melanoma and other skin tumoursIpilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial (2016) (8)
ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy. (2019) (8)
Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. (2015) (8)
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort (2021) (8)
Immunotherapy in non-melanoma skin cancer: updates and new perspectives (2019) (8)
Nevoid melanoma of the vagina: report of one case diagnosed on thin layer cytological preparations (2007) (8)
SO-8 Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair deficient advanced solid tumors: Results from the KEYNOTE-158 study (2021) (8)
A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL). (2013) (8)
The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial. (2020) (8)
Statement from the work session on chemically-induced alterations in the developing immune system: the wildlife/human connection. (1996) (8)
Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C). (2015) (8)
Sentinel Lymph Node Biopsy to Stage Patients with Cutaneous Melanoma at the National Cancer Institute of Naples. Results from 240 Sentinel Node Biopsies (2002) (8)
Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma. (2022) (8)
A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice in advanced melanoma patients progressing post anti-CTLA-4 therapy. (2013) (8)
A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial. (2015) (8)
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma (2022) (8)
3-year treatment with recombinant interferon-alpha as adjuvant therapy of cutaneous malignant melanoma. (1999) (8)
Management of Small and Intermediate Congenital Nevi: A Nationwide Survey in Italy (2013) (8)
The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials (2021) (7)
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. (2021) (7)
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy) (2018) (7)
Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) + vemurafenib (V) in the phase III IMspire150 study. (2020) (7)
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy) (2021) (7)
1222PDRegional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067) (2017) (7)
No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study (2020) (7)
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. (2021) (7)
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study (2020) (7)
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. (2022) (7)
Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511. (2021) (7)
Electrochemotherapy in melanoma patients: a single institution experience. (2015) (7)
Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice. (2015) (7)
Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. (2014) (7)
Anti-CTLA-4 probody BMS-986249 alone or in combination with nivolumab in patients with advanced cancers: Initial phase I results. (2020) (7)
An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238). (2019) (7)
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. (2021) (7)
Abstract CT012: Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients withBRAFV600mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial (2020) (7)
Melanoma recurrence after adjuvant targeted therapy: A multicenter analysis. (2020) (7)
Long-Term Outcomes in Patients With BRAF V 600-Mutant Metastatic Melanoma Receiving Dabrafenib Monotherapy : Analysis From Phase 2 and 3 Clinical Trials (2021) (7)
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment (2015) (7)
Developments in T Cell Based Cancer Immunotherapies (2015) (7)
Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma (2021) (7)
674PNivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032 (2017) (7)
Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib (2018) (7)
H05Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 (2015) (7)
491P Neoadjuvant nivolumab in early stage colorectal cancer (2020) (6)
Society for Melanoma Research 2015 Congress (2015) (6)
The European Ipilimumab Expanded Access Programme (EAP): Efficacy and Safety Data from the Italian Cohort of Patients with Pretreated, Advanced Melanoma (2012) (6)
Is there still a role for tremelimumab in the treatment of cancer (2013) (6)
Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study) (2017) (6)
LBA46 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial (2020) (6)
A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies. (2021) (6)
1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238 (2020) (6)
Vemurafenlb Improves Overall Survival Compared to Dacarbazlne In Advanced BRAFV600E-mutated Melanoma: Updated Survival Results From a Phase III Randomised, Open-label, Multlcentre Trial (2011) (6)
Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients (2015) (6)
ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors (2015) (6)
Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial. (2012) (6)
Identification of cases and estimate of direct costs of unresectable and advanced cutaneous squamous cell carcinoma: real‐world data from a large Italian database (2020) (6)
Lenvatinib combined with dacarbazine versus dacarbazine alone as first-line treatment in patients with stage IV melanoma. (2013) (6)
Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma. (2019) (6)
New‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy (2020) (6)
Epithelioid cell-type melanoma as a prognostic factor of poor response to immunological treatment. (2000) (6)
Phase II study SECOMBIT (sequential combo immuno and target therapy study): A subgroup analysis with a longer follow-up. (2022) (6)
Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib. (2019) (6)
3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC) (2015) (6)
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival (2021) (6)
A novel multiplex pyrosequencing assay for genotyping functionally relevant CTLA-4 polymorphisms: potential applications in autoimmunity and cancer. (2014) (6)
The Ratio of GrzB+ − FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma (2021) (6)
Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients (2020) (6)
The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases. (2012) (6)
The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma (2018) (6)
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma (2022) (5)
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma. (2022) (5)
Mutation frequency in BRAF and NRAS genes among primary tumors and different types of metastasis from melanoma patients. (2011) (5)
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop (2019) (5)
The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017 (2018) (5)
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma (2022) (5)
785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL) (2022) (5)
Evidence of publication bias in clinical trials of biotherapies for solid tumors (2005) (5)
Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience (2021) (5)
Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy. (2021) (5)
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. (2021) (5)
How we treat locoregional melanoma (2021) (5)
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III) (2021) (5)
The Future of Melanoma Therapy is the Combination Approach (2011) (5)
Efficacy and safety data from elderly patients with pretreated advanced melanoma in the Italian cohort of ipilimumab expanded access programme (EAP). (2013) (5)
Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600–mutant melanoma. (2017) (5)
Adverse event (AE) incidence rates with cobimetinib (C) plus vemurafenib (V) treatment: Extended follow-up (f/u) of the phase III coBRIM study. (2016) (5)
JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy (2021) (5)
Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases (2013) (5)
Impact of gene expression profiles on clinical predictors of survival in patients (pts) with BRAFV600-mutated metastatic melanoma (mM). (2017) (5)
1087OEFFICACY, SAFETY, AND QUALITY OF LIFE (QOL) DATA FROM THE EORTC 18071 PHASE III TRIAL OF IPILIMUMAB (IPI) VERSUS PLACEBO AFTER COMPLETE RESECTION OF STAGE III MELANOMA. (2014) (5)
Melanoma: prognostic factors and factors predictive of response to therapy. (2019) (5)
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). (2021) (5)
Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology (2019) (5)
Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization (2020) (5)
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma (2022) (5)
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. (2022) (5)
Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial. (2015) (5)
Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature (2020) (5)
Clinical predictors of response for coBRIM: A phase III study of cobimetinib (C) in combination with vemurafenib (V) in advanced BRAF-mutated melanoma (MM). (2016) (5)
Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection (2020) (5)
Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up (2021) (5)
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. (2022) (5)
The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic (2020) (4)
Activation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition (2014) (4)
Perspectives on COVID-19 and cancer immunotherapy: a review series (2021) (4)
Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation. (2014) (4)
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma (2022) (4)
Melanoma and immunotherapy bridge (2016) (4)
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. (2022) (4)
1102P Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study (2020) (4)
Anti-PD-1 antibody cetrelimab (JNJ-63723283) in patients with advanced cancers: Updated phase I/II study results. (2019) (4)
749P Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032 (2020) (4)
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238) (2018) (4)
Analysis of CTLA-4 gene polymorphisms in patients with advanced melanoma treated with anti-CTLA-4 therapy. (2011) (4)
Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes’ iTNF-α Expression (2021) (4)
Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAF V600: Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial. (2021) (4)
Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas (2022) (4)
Biology confirmed but biomarkers elusive in melanoma immunotherapy (2020) (4)
Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg (2014) (4)
MEK inhibition in BRAF-mutated melanoma. (2012) (4)
Targeted Therapies in Melanoma: Successes and Pitfalls (2013) (4)
The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019 (2020) (4)
Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (muts) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436). (2012) (4)
Prognostic subgroups and impact of treatment for post-progression overall survival (ppOS) in patients (pts) with BRAFV600-mutated metastatic melanoma treated with dacarbazine (DTIC) or vemurafenib (VEM) ± cobimetinib (COBI): A pooled analysis (2016) (4)
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment (2022) (4)
Melanoma: the role of surgery in the era of new therapies (2014) (4)
coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) (2014) (4)
COVID-19: A Paradigm Change (2020) (4)
Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib. (2014) (4)
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials (2020) (4)
Updates and new perspectives in nonmelanoma skin cancer therapy: highlights from 'Immunotherapy Bridge'. (2020) (4)
Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden (2022) (4)
Nivolumab for the treatment of small cell lung cancer (2020) (4)
Selecting immuno-oncology–based drug combinations – what should we be considering? (2018) (4)
Prognostic Value of CD 40 in Adult Soft Tissue Sarcomas (2004) (4)
Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma. (2013) (4)
The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients. (2010) (3)
Quality assurance in melanoma care: The EU-MELACARE study. (2018) (3)
Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from an ad-hoc expanded access program (EAP). (2018) (3)
The great debate at “Immunotherapy Bridge 2018”, Naples, November 29th, 2018 (2019) (3)
Circulating melanoma-associated markers detected by RT-PCR in patients with classic Kaposi's sarcoma. (2000) (3)
Diagnostic and Therapeutic Approaches in Italian Hospitals: Adjuvant and Metastatic Therapy in Melanoma (2013) (3)
BeyPro1: A phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with vemurafenib, with the association of vemurafenib plus fotemustine. (2014) (3)
Metronomic schedule of temozolomide with conventional dose of cisplatin in metastatic melanoma. (2009) (3)
Adjuvant therapy of melanoma: what's new? (2002) (3)
PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. (2022) (3)
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer (2014) (3)
9322 POSTER Immunological and Biological Changes and Their Correlation With Clinical Response and Survival During Ipilimumab in Metastatic Melanoma Compassionate Use Program (2011) (3)
Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East (2021) (3)
Enzyme activity of circulating CD73 in human serum. (2019) (3)
The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. (2020) (3)
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (2011) (3)
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. (2022) (3)
Combination approaches and anti-PD1 therapies: the focus of new research at ESMO and SMR. (2015) (3)
Feasibility of neoadjuvant electrochemotherapy for a large metastatic lesion of the cheek in a patient with melanoma (2012) (3)
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (3)
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma (2022) (3)
Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study. (2021) (3)
Adverse events of special interest in the phase 3 COLUMBUS study. (2018) (3)
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. (2023) (3)
Immunoscore as a parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients. (2020) (3)
Identifying prognostic subgroups for outcomes in BRAFV600-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) ± cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. (2016) (3)
Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI) (2020) (3)
Epidemiological and genetic factors underlying melanoma development in Italy. (2015) (3)
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (3)
Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program (2021) (3)
Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3. (2022) (3)
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (3)
A Metabolomics-Based Screening Proposal for Colorectal Cancer (2022) (3)
Editorial: Combination Strategies in the Treatment of Melanoma (2016) (3)
Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy. (2018) (3)
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers (2022) (3)
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (3)
The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg (2013) (3)
EURO-VOYAGE: Effectiveness and safety of ipilimumab (IPI) administered during a European Expanded Access Programme (EAP) in patients with advanced melanoma (MEL) (2017) (3)
NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug (2012) (3)
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation (2021) (3)
393 First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results (2020) (3)
Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study. (2022) (3)
Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 study. (2017) (3)
Title Effect of dabrafenib on melanoma cell lines harbouring the BRAF V 600 D / R mutations Permalink (2013) (3)
Erratum to: Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma (2014) (3)
Efficacy and safety of single agent pan-HER inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer (sSCC). (2017) (3)
Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study. (2019) (3)
The Italian Network for Tumor Biotherapy (NIBIT): Getting together to push the field forward (2008) (3)
Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172). (2016) (3)
1245PQuality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma (2017) (3)
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP) (2013) (3)
Molecular Pathogenesis of Melanoma: Established and Novel Pathways (2012) (3)
ipilimumab Versus Placebo After Complete Resection Of Stage Iii Melanoma: Efficacy And Safety Results From The Eortc 18071 Phase Iii Trial : 374 (2014) (3)
Abstract LB-094: Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma (2020) (3)
Health-related quality of life in patients with fully resected BRAFV600 mutation-positive melanoma receiving adjuvant vemurafenib. (2019) (3)
CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL). (2019) (3)
Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study (2022) (2)
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. (2022) (2)
Phase Ib/II study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy (2019) (2)
Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification (2013) (2)
What is changing in the adjuvant treatment of melanoma? (2017) (2)
1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047 (2021) (2)
Imaging Assessment of Interval Metastasis from Melanoma (2022) (2)
Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study. (2022) (2)
Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation. (2021) (2)
Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial. (2022) (2)
1090TiP A phase II, open label, multicenter study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with treatment-naïve metastatic Merkel cell carcinoma: The MERKLIN 1 study (2021) (2)
Significant differences in outcome between Immunoscore categories in stage I colon cancer patients. (2019) (2)
Low prevalence of microsatellite instability in malignant melanoma (2002) (2)
Immunotherapy followed by cetuximab in locally advanced/metastatic (LA/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial. (2022) (2)
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation (2021) (2)
Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial. (2022) (2)
Assessment of germline and somatic alterations in main candidate genes among patients with multiple primary melanoma (2014) (2)
Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/Rmutations (2013) (2)
Complete atrioventricular block in a patient with intracardiac metastases from malignant melanoma. (2011) (2)
Abstract 3677: Pattern and distribution of BRAF/NRAS and P16CDKN2Amutations among primary an secondary lesions in melanoma patients (2012) (2)
Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients (2021) (2)
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021 (2022) (2)
Diagnostic Services for Melanoma in Italy (2013) (2)
3342 Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE study (2015) (2)
SRF-CLICAL: an approach for patient risk stratification using random forest models (2021) (2)
Combination therapies in advanced melanoma. (2014) (2)
Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma (2015) (2)
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy) (2021) (2)
966P Diabetes therapy burden as proxy of impairment of immune checkpoint inhibitors efficacy (2021) (2)
Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) (2020) (2)
The nature and management of acquired resistance to PD1-based therapy in melanoma. (2020) (2)
fotemustine (FM) and dacarbazine (DTIC) versus DTIC ± interferon α in advanced malignant melanoma: A phase III study of the Southern Italy Cooperative Oncology Group (SICOG). (2006) (2)
Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19 (2021) (2)
1131TiPPHASE 1 STUDY EVALUATING SAFETY AND TOLERABILITY OF MEDI4736, AN ANTI-PROGRAMMED CELL DEATH LIGAND-1 (PD-L1) ANTIBODY, IN COMBINATION WITH DABRAFENIB AND TRAMETINIB OR TRAMETINIB ALONE IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA. (2014) (2)
Impact of Mole Mapping in the Italian Health System (2013) (2)
Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study. (2020) (2)
A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM). (2018) (2)
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials (2014) (2)
Meeting report from the “ Melanoma Research : a bridge from Naples to the World . Napoli , December 5 th – 6 th 2011 ” (2012) (2)
Multiplex immunohistochemistry assay to evaluate the melanoma tumor microenvironment. (2020) (2)
LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation (2022) (2)
Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy (2021) (2)
Metastatic endo and perineural involvement of the ulnar nerve from malignant melanoma: ultrasound (US) and magnetic resonance imaging (MRI) findings. (2021) (2)
Melanoma pathophysiology and drug targets (2012) (2)
Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors (2022) (2)
Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study (2018) (2)
1138P Delayed immune-related adverse events (irAEs) on anti-PD1-based therapy (2020) (2)
Economic evaluation of ipilimumab in first line treatment of advanced melanoma in Italy (2016) (2)
Elevated Levels of BRAFV600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma. (2018) (2)
307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study (2020) (2)
Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study. (2018) (2)
Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatment (2019) (2)
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma (2022) (2)
PCN84 COST OF ILLNESS OF CUTANEOUS SQUAMOUS CELL CARCINOMA IN ITALY (2019) (2)
Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors (2022) (2)
EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600–mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition. (2022) (2)
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study. (2022) (2)
Molecular Mechanisms Underlying the Action of Ipilimumab Against Metastatic Melanoma (2018) (2)
Ipilimumab and Stereotactic Radiosurgery with CyberKnife® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience (2021) (2)
Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma. (2020) (2)
Quality-of-Life (QoL) in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma (2017) (2)
Vemurafenib beyond progression in a patient with metastatic melanoma: a case report (2015) (2)
Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238. (2021) (2)
1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma (2021) (2)
Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave (2021) (2)
Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors (2018) (2)
Resistance to Targeted Therapies in Melanoma: New Insights (2013) (2)
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel (2022) (2)
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i) (2022) (2)
Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters (2013) (2)
Cost of illness of cutaneous squamous cell carcinoma (CSCC) (2020) (2)
Concomitant type 2 diabetes mellitus (T2DM) in metastatic melanoma patients could be related to lower level of Lag-3: a transcriptomic analysis on retrospective cohort. (2022) (1)
9328 The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients (2009) (1)
3346 BeyPro1: a Phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with Vemurafenib, with the association of Vemurafenib plus Fotemustine (2015) (1)
1018P Characterization of liver function tests following tebentafusp in phase III randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma (mUM) (2021) (1)
Microsatellite instability in melanocytic skin lesions (benign nevi, dysplastic nevi, and primari melanomas along with their metastases (2004) (1)
Electrochemotherapy in melanoma: a European e-Delphi survey to define a consensus on indications, treatment modalities and quality indicators (2019) (1)
Abstract P6-10-09: Mutational landscape of breast cancer patients in ROME trial: preliminary results (2023) (1)
Health-related quality of life (HRQoL) with pembrolizumab (pembro) in resected high-risk stage II melanoma in the phase 3 KEYNOTE-716 study. (2022) (1)
804P Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial (2022) (1)
Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study (2017) (1)
Abstract 2912: The isoform 2 of FKBP51 is induced by PDL-1/PD1 interaction and marks peripheral blood mononuclear cells of melanoma patients (2014) (1)
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM (2019) (1)
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment (2013) (1)
24 Nivolumab serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome (2021) (1)
The immune score as a new possible approach for the classification of cancer (2012) (1)
Predictors of response to checkpoint inhibitors in naïve and ipilimumab-refractory melanoma (2019) (1)
Cost of illness del carcinoma cutaneo a cellule squamose (CSCC) (2020) (1)
546 Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM) (2021) (1)
Letter Regarding Editorial by Samuel Zagarella. (2020) (1)
What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO) (2016) (1)
An Open-Label, Multicentre Safety Study of Vemurafenib in Patients with Metastatic Melanoma (2012) (1)
Ipilimumab in the Treatment of Metastatic Melanoma: A Summary of Recent Studies (2013) (1)
Mobile hospital rooms to fight melanoma. (2001) (1)
Drug Repurposing to Target the Apoptosome in MAPKi-Resistant Melanoma (2021) (1)
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future? (2017) (1)
Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K) (2023) (1)
What have we learned from cancer immunotherapy in the last 3 years? (2014) (1)
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use (2012) (1)
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma (2013) (1)
Abstract 4017: Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma (2016) (1)
Assessment of microsatellite instability in benign nevi, dysplastic nevi, and primary melanomas along with their metastases (2003) (1)
Lean oncology: a new model for oncologists (2012) (1)
Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma (2017) (1)
PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab (2022) (1)
How do immune checkpoint-targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studies. (2018) (1)
Adjuvant treatment with interferon-α in melanoma stage II–III: experience of melanoma cooperative group (1999) (1)
Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T). (2019) (1)
MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab (2014) (1)
551 Pegasus Skin, a study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL2) with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers (2021) (1)
Abstract CT016: MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study (2022) (1)
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials (2014) (1)
70MO Genomic profiling to expand precision cancer medicine in the real world: The ROME trial (2023) (1)
Tumor biobanks in translational medicine (2012) (1)
Are there, or shall we discover, biomarkers to guide PD-1 inhibition? (2016) (1)
Expression of CD73 on MDSCs and CD8+/PD-1+ cells as new possible biomarkers for advanced melanoma patients treated with nivolumab (2018) (1)
The cost of unresectable stage III or stage IV melanoma in Italy (2012) (1)
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort (2021) (1)
Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021 (2022) (1)
Abstract 558: Prognostic gene signature use in checkpoint inhibitor monotherapy for melanoma (2018) (1)
79O Clinical performance of Immunoscore® in early colon cancer in the Asian population (2020) (1)
A phase II, open-label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study. (2021) (1)
Editorial: Advancements in Molecular Diagnosis and Treatment of Melanoma (2021) (1)
The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020 (2021) (1)
Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients (2015) (1)
Systemic gut microbial metabolites limit the anti-tumour effect of CTLA-4 blockade in hosts with cancer (2019) (1)
ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy (2019) (1)
Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts (2019) (1)
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme (2014) (1)
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma (2018) (1)
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma (2015) (1)
Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma (2022) (1)
Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]. (2018) (1)
959 Expression of functional CXCR4 on colorectal human cancer (2003) (1)
The role of BRAF V600 mutation in melanoma (2012) (1)
UV exposure and melanoma prognostic factors : results from Clinical National Melanoma Registry (CNMR) (2014) (1)
Increased HOX C13 expression in metastatic melanoma progression (2012) (1)
Immunoscore as new possible approach for the classification of melanoma. (2014) (1)
819P Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial (2022) (1)
Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization (2022) (1)
New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): review of the literature and single-center experience. (2021) (1)
The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates (2020) (1)
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy) (2021) (1)
ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors (2015) (1)
Report from the Melanoma Independent Board First Melanoma MIB Conference, 21–22 October 2013 (2014) (1)
Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma (2018) (1)
Discrepant alterations in main candidate genes among multiple primary melanomas (2014) (1)
ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. (2018) (1)
Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM) (2019) (1)
Weighing the role of concomitant medications during PD-1/PD-L1 checkpoint blockade: A preliminary analysis. (2020) (1)
Abstract 1070: miR-579-3p is a novel master regulator of melanoma progression and drug resistance in metastatic melanoma (2016) (1)
Preoperative nivolumab in patients(pts) with locally advanced colon cancer (T3 or T4): A window-of-opportunity study (NICOLE). (2018) (1)
Genomic scale analysis of NK cells impact on response to IFN-α (2013) (1)
NF-κB as potential target in the treatment of melanoma (2012) (1)
Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care (2017) (1)
Molecular Classification of Patients with Cutaneous Melanoma: A Reality (2012) (1)
Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021 (2022) (1)
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme (2013) (1)
PP 65 Are GSK2118436 and GSK1120212 effective in melanoma cell lines harboring V600BRAF mutations different from the common V600EBRAF variant (2011) (1)
Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies (2013) (1)
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC) (2022) (1)
Immunotherapy Assessment: A New Paradigm for Radiologists (2023) (1)
Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma (2014) (1)
Patient-reported outcomes (PROs) from the phase III IMspire150 trial of atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in patients (pts) with BRAFV600+melanoma. (2020) (1)
The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019 (2020) (1)
[Using Twitter in oncology. Research, continuing education, and advocacy]. (2015) (1)
Sonic hedgehog pathway for the treatment of inflammatory diseases: implications and opportunities for future research (2022) (1)
Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor pembrolizumab and trastuzumab in preclinical models (2019) (1)
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma (2013) (1)
Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma. (2019) (1)
Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma previously exposed to anti–PD-1/PD-L1 agents: Phase 2 LEAP-004 study. (2019) (1)
Melanoma: From Research to Treatment (2012) (1)
High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab (2014) (1)
EP-1392: The abscopal effect:efficacy of radiotherapy in patients on progression after ipilimumab 3 mg/kg (2016) (1)
Do BRAF inhibitors select for populations with different disease progression kinetics? (2013) (1)
Emerging Therapeutics for Melanoma (2012) (1)
Abstract B16: NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with advanced NRAS-mutant melanoma who are untreated or have progressed on or after immunotherapy (2015) (1)
1065P A retrospective multicenter Italian analysis of the effect of longer vismodegib intake in 68 basal cell carcinoma patients who achieved clinical complete remission (2021) (1)
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018 (2019) (1)
871P Predictive role of neutrophil-lymphocyte ratio (NLR) in patients (pts) with metastatic melanoma: A post hoc exploratory analysis from phase III COMBI-i trial (2022) (1)
Low doses interferon-α in the treatment of high-risk cutaneous melanoma (2000) (1)
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma (2015) (1)
PO-0741: Ipilimumab and stereotactic radiosurgery with cyberknife in melanoma brain metastases (2017) (1)
Low doses interferon-alpha in the treatment of high-risk cutaneous melanoma. Melanoma Cooperative Group. (2000) (1)
Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients (2015) (1)
Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma (2018) (1)
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 (2022) (1)
Melanoma: the role of surgery in the era of new therapies (2014) (1)
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply. (2021) (1)
NEMO: A Phase 3 Trial of Binimetinib (MEK162) Versus Dacarbazine in Patients With Advanced NRAS-Mutant Melanoma Who Are Untreated or Have Progressed After Immunotherapy (2014) (1)
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021 (2022) (1)
Cancer classification using the Immunoscore: a worldwide task force (2012) (1)
1074P Italian nivolumab Expanded Access Program (EAP) in melanoma adjuvant setting: Patients outcomes and safety profile (2021) (1)
Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study (2013) (1)
Surgical Management of Suspicious Melanocytic Lesions in Italy (2013) (1)
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer (2020) (1)
Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from an ad hoc expanded access program (EAP) (2018) (1)
Expansion of a lymphocyte subset expressing a spliced FKBP51 isoform in melanoma patients. (2015) (1)
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice (2019) (0)
The “Great Debate” at Immunotherapy Bridge 2020, December 3rd, 2020 (2021) (0)
#3677 Ptttern and distribution of BRAF/I{RAS and Pl6cDN2A mutations among primary an secondary lesions in melanoma patients. Antonella (2012) (0)
Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma - Authors' reply. (2023) (0)
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned (2023) (0)
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer. (2023) (0)
Mutation analysis of mucosal and cutaneous melanomas during progression. (2017) (0)
About the role of the epiluminescent microscopy in the early diagnosis of the cutaneous malignant melanoma: 289 (1997) (0)
9320 Treatment with intravenous High Dose Interferon (HDI) is able to reduce levels of circulating regulatory T (Treg) cells in melanoma patients (2009) (0)
Nevus changed by recurrent Herpes simplex infection: Reflectance confocal microscopy (2014) (0)
The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020 (2021) (0)
The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates (2021) (0)
Medication related jaw osteonecrosis (MRONJ) late onset 3 years after IPILIMUMAB endovenous administration: a possible role of target therapy (2020) (0)
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies (2023) (0)
Corrigendum to "Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma" [Eur J Canc 157 (2021) 250-258]. (2022) (0)
50th Anniversary of Acta Haematologica (1998) (0)
Role of CXCR4 in melanoma: A prognostic factor and a new target of therapy (2006) (0)
The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021 (2022) (0)
21 IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy – a real life study (2022) (0)
Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma (2019) (0)
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment (2015) (0)
1574P Mortality of 1,636 COVID-19 cancer patients (pts) and associated prognostic factors (2021) (0)
An imaging study of vemurafenib in patients with BRAFV600-mutated metastatic melanoma. (2017) (0)
Abstract 5529: Proteomic profiling of FFPE tumors samples from melanoma subjects treated with anti-PD-1 immunotherapy identifies proteins associated with response to treatment (2020) (0)
864P Prognostic impact of MARCO and OAS1 expression in metastatic melanoma patients treated with anti-PD1: A proteomics and transcriptomics retrospective analysis (2022) (0)
1127P Correlation of BRAF mutation status in circulating tumour DNA (ctDNA) with tumour biopsy and clinical outcomes in COLUMBUS (2020) (0)
Future perspectives in melanoma research (2016) (0)
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy) (2021) (0)
Evaluation of genetic heterogeneity in paired lymph node metastases from melanoma patients using next-generation sequencing (NGS) approaches. (2015) (0)
Dendritic cell (DC) vaccination with low dose temozolomide phase I/II trial in melanoma patients: Preliminary data on peripheral blood regulatory t-cells (Treg) and DC-TEM8 expression modulations. (2011) (0)
Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (0)
Definition of new tumor progression markers in malignant melanoma (MM) (1999) (0)
1109PVEMURAFENIB IN BRAFV600 MUTATED METASTATIC MELANOMA (MM): A SUBANALYSIS OF THE ITALIAN POPULATION OF A GLOBAL SAFETY STUDY. (2014) (0)
1137P Incidence and time course of adverse events (AEs) with atezolizumab (A) in combination with vemurafenib (V) and cobimetinib (C) in the phase III IMspire150 study (2020) (0)
Genetic alterations at chromosome 9p21 and melanoma progression (2007) (0)
The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021 (2022) (0)
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients (2013) (0)
Unusual sites of metastases from melanoma. US and CT findings. (2011) (0)
Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]. (2021) (0)
Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg (2014) (0)
Genetic analysis of sporadic and familial malignant melanoma (MM): assessment of the role of 9p21 region and p16/CDKN2A gene in MM tumorigenesis and its clinicopathological correlation (2001) (0)
Abstract CT001: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial (2018) (0)
Advances in immunotherapy for melanoma. (2014) (0)
Melanoma Bridge 2013: Poster and Oral Presentations (2014) (0)
Melanoma Bridge 2013: Poster and Oral Presentations (2014) (0)
239 Efficacy and toxicity of single agent immune checkpoint inhibitors among adults with cancer aged ≥80 years: a multicenter international cohort study (2021) (0)
Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238. (2023) (0)
[Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market] (2016) (0)
In Search of Predictive Biomarkers in Cancer Immunotherapy (2019) (0)
Mutation Analysis of Candidate Genes in Familial Cases with Malignant Melanoma: Identification of An Additional Susceptibility Region at Chromosome 9p21 (2004) (0)
Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study (2019) (0)
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. (2023) (0)
Correlation of nivolumab 480 mg Q4W with better survival than other nivolumab monotherapy schedule in metastatic melanoma patients. (2020) (0)
1665P Genomic mutational landscape of solid tumors: Preliminary results from ROME trial (2022) (0)
Functional interactions of the MAPK-ERK gene patway in melanoma patients (2006) (0)
Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. (2023) (0)
What’s new in melanoma? Combination! (2015) (0)
Abstract CT197: Phase Ib study of LXH254 + trametinib (TMT) in patients (pts) with NRAS-mutant melanoma (2022) (0)
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016 (2017) (0)
Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM). (2022) (0)
[Reply to Letter to the Editor in reference to " Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market”] (2017) (0)
Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7–9, 2010 (2011) (0)
Identification of potential predictive biomarkers of rapid progression and rapid response to anti-PD1 treatment by gene profiling analysis in metastatic melanoma patients. (2020) (0)
FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” (2012) (0)
CommentaryA model for testing new agents in combination therapies (2010) (0)
Corrigendum to “Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI)” [Eur J Canc 137 (2020). Pages 30–39] (2020) (0)
Detection of tyrosinase mRNA in tumor tissue microdissections from classic Kaposi's sarcoma. (2001) (0)
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (0)
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (0)
Immunogenicity and Safety of the Prame Cancer Immunotherapeutic in Metastatic Melanoma: Phase I/II Dose Escalation Study (2012) (0)
1153TiP A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study (2020) (0)
Extracellular Matrix Molecules as Targets for Melanoma Therapy (2012) (0)
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (0)
The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022 (2023) (0)
592 Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: part 1 results (2022) (0)
The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic (2020) (0)
Abstract CT069: Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma (2023) (0)
Front & Back Matter (2012) (0)
Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) (2020) (0)
Could wide tattoo delay the early diagnosis of cutaneous melanoma? (2023) (0)
Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis (2013) (0)
Spartalizumab in Combination With Dabrafenib And Trametinib in Advanced BRAF V600–Mutant Melanoma: Efficacy, Safety, and Biomarker Findings in Parts 1 and 2 of COMBI-i (2020) (0)
Subgroup analysis of patients (pts) with Gorlin syndrome treated with vismodegib (VISMO) in the STEVIE study (2016) (0)
Efficacy and Safety of Ipilimumab Reinduction Therapy Patients with Pretreated Advanced Melanoma Participating in an Expanded Access Programme (EAP) in Italy (2012) (0)
Abstract PL02-01: What we learned from immunotherapy in previous years (2015) (0)
884TiP A phase Ib/II multicenter, randomized, umbrella study evaluating novel treatment combinations in melanoma (MORPHEUS-MELANOMA) (2022) (0)
Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization (2020) (0)
Cisplatin (CDDP), dacarbazine (DTIC), interferon (IFN) and amifostine (AMI) in advanced melanoma. A phase I study (1999) (0)
Immunotherapy in Melanoma (2021) (0)
The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma (2014) (0)
Introduction: General Approach to Cancer Immunotherapy—Lessons Learned From the Past Years (2021) (0)
Different prevalence of BRAF and NRAS somatic mutations in melanomas according to the patients’ origin. (2013) (0)
Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance (2022) (0)
Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB/C or IV melanoma: Analysis of CheckMate 238 four-year follow-up (FU) data. (2021) (0)
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy) (2021) (0)
EPIDEMIOLOGY, GENETICS AND PATHOGENESIS A01 FAMILIAL MELANOMA AND MULTIPLE PRIMARY MELANOMA: ANALYSIS OF PREDISPOSING GENETIC MUTATIONS IN 190 PATIENTS (2021) (0)
Fanconi genes may contribute to melanoma pathogenesis (2007) (0)
Prognostic and predictive value of metformin in the EORTC 1325/KEYNOTE- 054 phase III trial of pembrolizumab vs placebo in resected high-risk stage III melanoma (2023) (0)
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment (2014) (0)
Report from the second MIB (Melanoma Independent Board) Conference, 27–28 October 2014 (2015) (0)
Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma (2014) (0)
[Treatment of loco-regional lymph nodes in cutaneous melanoma]. (2002) (0)
Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+ T cells (PD1tR) driven by tumour CD155 (2019) (0)
Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis (2021) (0)
Melanoma and immunotherapy bridge 2015 (2016) (0)
Reduction of circulating regulatory T cell (Treg) by intravenous high-dose interferon (HDI) treatment in melanoma patients. (2009) (0)
Melanoma and immunotherapy bridge 2015 (2016) (0)
934 Biological mechanisms in the different etiologies of Merkel cell carcinoma patients: polyomavirus or UV exposure (2021) (0)
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy) (2018) (0)
Abstract 2672: Early evaluation of response to Vemurafenib treatment with FDG PET/CT in patients with metastatic melanoma. (2013) (0)
833P Longer follow up of a real-world study of cemiplimab in advanced cutaneous squamous cell carcinoma: Focus on late toxicities and long term benefit (2022) (0)
P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma (2020) (0)
813P Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) + cobimetinib (C): Updated results from the phase III IMspire150 study (2022) (0)
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort (2014) (0)
Abstract 1623: Response and skin toxicity related protein signature in late stage melanoma patients after anti-PD-1 treatment (2021) (0)
From genetics to physiopathology of malignant melanoma (MM): assessment of the role of known genes (p16, CDK4, Id-1) and identification of a new candidate locus on chromosome 9p21 through combined genomic and functional approaches (2002) (0)
The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022 (2023) (0)
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma (2019) (0)
301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study (2020) (0)
Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification (2014) (0)
Polymerase C hain R eaction-Based D etection o f C irculating Melanoma C ells a s a n Effective M arker of T umor P rogression (1999) (0)
Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells (2017) (0)
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade (2019) (0)
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab (2023) (0)
Assessment of germline and somatic alterations in main candidate genes among patients with multiple primary melanoma (2012) (0)
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015 (2016) (0)
CXCR4 in melanoma: A prognostic biomarker and a target of therapy. (2006) (0)
740P Anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249 ± nivolumab (NIVO) in patients (pts) with advanced cancers: Updated phase I results (2022) (0)
Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma (2015) (0)
European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma. (2023) (0)
Immunotherapies and Novel Combinations (2019) (0)
774 A phase 1 study exploring the safety and tolerability of the small molecule PD-L1 inhibitor, INCB086550, in patients with select advanced tumors (2022) (0)
1042P Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts) (2021) (0)
Immuno-related adverse events (irAE) from check-Point inhibitors during immunotherapy for cancer. Imaging Findings. (2018) (0)
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 (2015) (0)
Anti-IL6R role in treatment of COVID-19-related ARDS (2020) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy) (2021) (0)
838P Patterns of response/progressive disease (PD) and management following PD with anti-PD-1 (PD1) in patients (pts) with advanced cutaneous squamous cell carcinoma (cSCC) (2022) (0)
The Clinical and Translational Research Activities at the INT – IRCCS “Fondazione Pascale” Center (Naples, Italy) during the COVID-19 Pandemic (2020) (0)
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas (2015) (0)
The early diagnosis of cutaneous malignant melanoma: The role of the epiluminesent microscopy (1997) (0)
Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach (2019) (0)
Reply to E. Hindié. (2021) (0)
MUTATIONANALYSISOFCANDIDATEGENES IN FAMILIAL CASESWITHMALIGNANTMELANOMA: IDENTIFICATIONOFAN ADDITIONALSUSCEPTIBILITYREGIONATCHROMOSOME9P21 (2004) (0)
Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al (2022) (0)
How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma? (2022) (0)
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells (2017) (0)
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018 (2019) (0)
842 Development of a multiplex test for predicting response to combined immunotherapies in patients with metastatic melanoma (2022) (0)
704TiP SAR445256 (KY1044) in combination with atezolizumab in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) (2022) (0)
UV exposure and melanoma prognostic factors : results from Clinical National Melanoma Registry (CNMR) (2014) (0)
Activation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition (2014) (0)
Proteomics meets transcriptomics: Identification of tumor tissue signatures specific to anti-PD1 treatment in late-stage melanoma patients. (2021) (0)
817P Nivolumab (NIVO) + relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047 (2022) (0)
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation (2021) (0)
A phase II trial of dacomitinib in locally advanced unresectable or metastatic skin squamous cell carcinoma. (2017) (0)
A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI). (2015) (0)
Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16–18 October 2008 (2009) (0)
BiomarkersforImmunostimulatoryMonoclonalAntibodiesin C ombination S trateg ies for Melanoma and O th er T umor T yp es (2013) (0)
Low-dose temozolomide modulation of peripheral blood regulatory T cells before dendritic cell-based vaccination in metastatic melanoma: Phase I/II study. (2010) (0)
Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients (2020) (0)
Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis (2022) (0)
Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer (2023) (0)
1241PImpact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C+V): a pooled analysis (2017) (0)
Skin-directed electrochemotherapy: A prospective multi-institutional study on 394 patients with superficial tumors. (2015) (0)
Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19–22, 2011: New perspectives in the immunotherapy of cancer (2012) (0)
308 Transcriptomic analysis of melanoma patients in adjuvant setting treated with anti PD1 therapy: real life study (2021) (0)
Adjuvant Therapy in Resected Melanoma. (2018) (0)
Enhancing T Cell Performance Against Cancer in Combination Treatment Strategies (2015) (0)
Main Plenary Sessions (2015) (0)
P-26 Predictors of germline mutations in candidate genes among patients with malignant melanoma from south Italy (2007) (0)
KY1044 to target the ICOS pathways inducing intratumoral Treg depletion and agonism of effector T cells: Preliminary pharmacodynamic markers from a phase 1/2 multicenter trial. (2021) (0)
Immunotherapy (2021) (0)
The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021 (2022) (0)
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013 (2014) (0)
1091TiP STARBOARD: Randomized phase III study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma (2021) (0)
Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC) (2022) (0)
New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer (2023) (0)
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy (2017) (0)
Common Toxicities associated with Immune Checkpoint Inhibitors and Targeted Therapy in the Treatment of Melanoma: A Systematic Scoping Review. (2023) (0)
Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study. (2023) (0)
Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma (2020) (0)
786O Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma (2022) (0)
The “Great Debate” at Immunotherapy Bridge 2020, December 3rd, 2020 (2021) (0)
Adjuvant treatment of melanoma using placebo or no therapies as control-arm: is it ethically correct? (1999) (0)
Dermatologic adverse events associated with targeted therapies for melanoma (2021) (0)
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. (2023) (0)
Detect ion of Occul t Melanoma Cel ls in Paraffin-Embedded Histo logica (2001) (0)
Detection o f O ccult M elanoma C ells i n P araffin-Embedde d Histologically N egative S entinel L ymph N odes U sing a Reverse T ranscriptase P olymerase C hain R eaction A ssay (2013) (0)
113P Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial (2022) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) (2022) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) (2022) (0)
Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis (2017) (0)
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012 (2013) (0)
1259TiPA randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i) (2017) (0)
Correlation of polymorphic variants into the susceptibility of CDKN2 locus with melanoma outcome. (2010) (0)
Cytogenetic analysis at chromosome 9p21 on tissue sections from patients with malignant melanoma (2004) (0)
3343 Exploratory analysis of vismodegib (VISMO) treatment discontinuation in the STEVIE study (2015) (0)
Ipilimuamb Treatment after Electrochemotherapy Could be An Effective Sequential Combination Approach (2012) (0)
Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave (2021) (0)
Mutation frequencies in a gene panel among primary tumors and metastases in patients with melanoma. (2018) (0)
G1 A phase II trial of dacomitinib in locally advanced unresectable or metastatic skin squamous cell carcinoma G2 Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma a retrospective single (2017) (0)
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016 (2017) (0)
May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)? (2020) (0)
The influence of diet on anti-cancer immune responsiveness (2018) (0)
Targeting the MITF/APAF-1 axis as salvage therapy for MAPK inhibitors in resistant melanoma. (2022) (0)
Abstract P5-12-08: Not presented (2019) (0)
The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014 (2014) (0)
Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study (2019) (0)
Abstract CT405: Experience in using oncology drugs in patients with COVID-19 (2020) (0)
Potential strategies for overcoming tumor immune evasion mechanisms and examples of agents in clinical development (2014) (0)
761 Potential predictive biomarkers of rapid progression and response to anti-PD1 treatment by gene profiling analysis in metastatic melanoma patients (2020) (0)
CXCR4 in melanoma progression: A prognostic factor and a new target of therapy. (2005) (0)
Consultant Oral Session Abstracts (2018) (0)
B09Efficacy and safety of single agent pan-HER inhibitor Dacomitinib in the treatment of unresectable or metastatic skin squamous cell cancer – Trial in progress (2015) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy) (2021) (0)
The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021 (2022) (0)
The ACC melanoma pilot project: “Real-world” evaluation of an NGS platform for molecular characterization of melanoma in Italy. (2019) (0)
Multiple Primary Melanomas from Same Patients Present Discrepant Somatic Alterations in Main Candidate Genes (2012) (0)
Therapeutic Targeting of the Bone Pre-metastatic Niche (2013) (0)
Prognostic relevance of baseline neutrophils and derived neutrophil to lymphocyte ratio for ipilimumab-treated advanced melanoma patients. (2015) (0)
Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatment (2019) (0)
Vaccine: What's news? (Vaccini: Quale futuro?) (2007) (0)
Advances in Cancer Immunotherapy (2016) (0)
Oral immune-related adverse events caused by immune checkpoint inhibitors: a retrospective study. (2022) (0)
Real Life Clinical Management and Survival in Cutaneous Malignant Melanoma: the Italian Clinical National Melanoma Registry (CNMR) Experience (2020) (0)
BRAF gene contributes to melanoma pathogenesis but not to melanoma susceptibility. (2004) (0)
Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) + vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation–positive advanced melanoma. (2021) (0)
Prognostic V alue o f C irculating M elanoma C ells D etected b y Reverse T ranscriptase-Po lymerase C hain R eaction (2003) (0)
CD73 activity and outcome of advanced melanoma patients treated with nivolumab (2018) (0)
Marker utility for combination therapy. (2014) (0)
R22Immunotherapy (ImT), what Lung Cancer and Melanoma patients (pts) … and physicians, know (2015) (0)
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma (2016) (0)
606 Biomarker analyses of baseline tumor specimens and on-treatment changes in sera samples of patients enrolled in the RELATIVITY-047 trial to characterize LAG-3 biology (2022) (0)
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (2021) (0)
229 Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy (2020) (0)
840P Electronic patient-reported outcomes (ePROs) of adults with BRAF V600–mutant stage III-IV melanoma treated with dabrafenib + trametinib (D + T) collected using the Kaiku Health digital patient (pt) monitoring platform (2022) (0)
Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study (2022) (0)
THE COMBINATION THERAPY OF ANTI-PD1 ANTIBODY PEMBROLIZUMAB AND ANTI-HER2 ANTIBODY TRASTUZUMAB EXERTS CARDIOTOXIC, PRO-INFLAMMATORY AND PRO-FIBROTIC PROPERTIES IN PRECLINICAL MODELS (2020) (0)
BRAE NRAS and p/6cDrN2'{ mutations among primary and secondary melanomas from same patients (2011) (0)
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1–3 October 2009 (2010) (0)
112 Circulating and molecular markers of inflammation: impact on treatment response and survival among older patients with cancer treated with immune checkpoint inhibitors (2022) (0)
Melanoma and Cutaneous Malignancies Characterization andManagement of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma (2016) (0)
308 Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma (2020) (0)
Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy? (2017) (0)
Safety and Efficacy of Ipilimumab 10 Mg/Kg Among Patients with Advanced Melanoma from Italy Enrolled in a European Compassionate Use Program (2012) (0)
Immunoscore predicts significant differences in time to recurrence in stage I colon cancer patients (2019) (0)
Abstract 2624: An FKBP5-based immunophenotype for assessment of the immunosuppression status and possible prediction of immunotherapy response in melanoma patients (2017) (0)
Safety and Regulation of Immune Checkpoint Inhibitors in Special Patient Populations (2019) (0)
9313 NEMO-binding domain peptide induces apoptosis in human melanoma cells: an effect associated to inhibition of constitutive NF-kappaB activation (2009) (0)
PCN57 A MULTI-STAKEHOLDER PERSPECTIVE ON THE CHALLENGES IN DEMONSTRATING THE LONG-TERM BENEFIT OF CANCER IMMUNOTHERAPY (2019) (0)
Serial RT-PCR detection of circulating tumour cells as a marker of disease progression in patients with malignant melanoma. (2006) (0)
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma (2022) (0)
882TiP Subcutaneous vs intravenous nivolumab in patients with melanoma following complete resection (2022) (0)
World-Wide Immunoscore Task Force: meeting report from the “Melanoma Bridge”, Napoli, November 30th–December 3rd, 2016 (2017) (0)
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (0)
Overcoming anti-melanoma drug resistance with reverse transcriptase inhibitors (RTIs) (2020) (0)
836P Outcome of PD-1 inhibitor therapy of advanced melanoma patients according to demographic factors in a real-world setting across Europe (2022) (0)
Involvement of NK cell molecular signatures in favorable prognosis of breast cancer patients. (2012) (0)
New paradigm for stage III melanoma: from surgery to adjuvant treatment (2019) (0)
Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients (2012) (0)
[Cutaneous squamous cell carcinoma: immunotherapy for locally advanced and metastatic disease]. (2020) (0)
Variations of Vaccinia Virus' Replication in Melanoma and Lung Cell Lines Based on Different Expression of IFI6, and IFTMN2 and β-microglobin (2010) (0)
Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program (2021) (0)
Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients (2013) (0)
The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017 (2018) (0)
Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma (2012) (0)
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy) (2019) (0)
42TiP A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitors (2022) (0)
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab (2017) (0)
Novel blood-based biomarker predicting severe toxicity in melanoma anti-CTLA-4 immunotherapy treatment. (2020) (0)
Analysis of the mapk-erk gene pathway in primary and metastatic melanoma cell lines (2006) (0)
Targeting Tumor Angiogenesis (2013) (0)
Early FDG PET/CT monitoring of patients with metastatic melanoma undergoing vemurafenib treatment (2013) (0)
Role of the EGF + 61 A > G polymorphism in melanoma pathogenesis : an experience on a large series of Italian cases and controls (2015) (0)
O-17 A TNM-Immune (TNM-I) classification staging system for predicting survival in colon cancer in a multicenter international SITC study (2020) (0)
EP-1396: Radiosurgery/Stereotacticradiotherapy with Cyberknife and immunotherapy in melanoma brain metastases (2016) (0)
Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study. (2019) (0)
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma (2023) (0)
BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. (2022) (0)
Kerion Celsi favored by the use of a tretinoin+minoxidil+betamethasone valerate lotion in a 28-year-old woman. (2010) (0)
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study (2023) (0)
Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma (2021) (0)
Molecular classification for the management of melanoma patients (2008) (0)
Melanoma health care pathways in an italian population (2013) (0)
1084P PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma (2021) (0)
Cancer immunotherapy: from the lab to clinical applications—Potential impact on cancer centres’ organisation (2016) (0)
Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection (2020) (0)
Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review (2021) (0)
Abstract A79: Expression of argininosuccinate synthetase (ASS) and response to arginine deiminase (ADI) treatment in a series of melanoma cell lines (2009) (0)
PCN40 Healthcare Resource Utilization in Patients Treated with Encorafenib PLUS Binimetinib for BRAF-Mutant Metastatic Melanoma: DATA from Columbus, a Phase 3 Trial in BRAF-Mutant Melanoma (2020) (0)
The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019 (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Paolo Antonio Ascierto?

Paolo Antonio Ascierto is affiliated with the following schools:

MD Anderson Cancer Center
University of Sydney
University of Wales
University of Sassari
Johns Hopkins University
University of Naples Federico II

Paolo Antonio Ascierto's Academic­Influence.com Rankings

Paolo Antonio Ascierto's Degrees

Why Is Paolo Antonio Ascierto Influential?

Paolo Antonio Ascierto's Published Works

Published Works

What Schools Are Affiliated With Paolo Antonio Ascierto?

Paolo Antonio Ascierto's AcademicInfluence.com Rankings